You have 9 free searches left this month | to do more

bevacizumab

Bevacizumab is a drug used to treat Colorectal Cancer, Breast Cancer, Ovarian Cancer, and other conditions. Bevacizumab is being actively studied in 302 studies and prior, has been studied in 697.

Top SponsorsTop SitesTop Investigators
National Cancer Institute (NCI)Dana-Farber Cancer InstituteDuNan
Hoffmann-La RocheWashington University School of MedicinePeter C. Enzinger, MD
M.D. Anderson Cancer CenterMassachusetts General HospitalVassilis Georgoulias, MD
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
2022-03-10
Mar 10, 2022
M
Recruiting
  • BRAF V600 Wild Type
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-01
Mar 1, 2022
M
Active, not recruiting
  • Invasive Breast Carcinoma
  • Triple-Negative Breast Carcinoma
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-18
Feb 18, 2022
M
Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +5 more
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-24
Feb 24, 2022
N
Recruiting
  • Advanced Papillary Renal Cell Carcinoma
  • +6 more
  • Atezolizumab
  • +2 more
  • Bethesda, Maryland
    National Cancer Institute LAO
2021-10-15
Oct 15, 2021
N
Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Bevacizumab
  • +2 more
  • Los Angeles, California
  • +17 more
2022-01-25
Jan 25, 2022
N
Recruiting
  • Metastatic Colorectal Carcinoma
  • +4 more
  • Bevacizumab
  • +4 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-12-14
Dec 14, 2021
N
Recruiting
  • Combined Hepatocellular Carcinoma and Cholangiocarcinoma
  • +4 more
  • Atezolizumab
  • +3 more
  • Danville, Illinois
  • +5 more
2022-03-30
Mar 30, 2022
N
Active, not recruiting
  • Adult Glioblastoma
  • +23 more
  • Bevacizumab
  • +3 more
  • Boston, Massachusetts
  • +2 more
2021-11-17
Nov 17, 2021
C
Recruiting
  • Locally Advanced Lung Non-Small Cell Carcinoma
  • +9 more
  • Duarte, California
  • +3 more
2021-11-15
Nov 15, 2021
A
Active, not recruiting
  • Metastatic Colorectal Carcinoma
  • +5 more
  • Phoenix, Arizona
  • +9 more
2022-01-05
Jan 5, 2022
M
Active, not recruiting
  • Appendix Adenocarcinoma
  • +20 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-25
Feb 25, 2022
K
Not yet recruiting
  • Carcinoma, Ovarian Epithelial
  • pembrolizumab
  • +5 more
  • (no location specified)
2021-12-09
Dec 9, 2021
M
Recruiting
  • Cervical Adenocarcinoma
  • +47 more
  • Bevacizumab
  • +3 more
  • Phoenix, Arizona
  • +3 more
2022-01-07
Jan 7, 2022
N
Active, not recruiting
  • Fallopian Tube Endometrioid Adenocarcinoma
  • +7 more
  • Anetumab Ravtansine
  • +2 more
  • Orange, California
  • +22 more
2022-04-05
Apr 5, 2022
N
Active, not recruiting
  • Recurrent Glioblastoma
  • Bevacizumab
  • +3 more
  • La Jolla, California
  • +26 more
2022-03-25
Mar 25, 2022
N
Recruiting
  • Peritoneal Malignant Mesothelioma
  • Atezolizumab
  • +5 more
  • Chicago, Illinois
  • +8 more
2022-03-15
Mar 15, 2022
T
Recruiting
  • Ovarian Cancer
  • Bevacizumab
  • +2 more
  • Tai'an, Shandong, China
    The Second Affiliated Hospital of Shandong First Medical Univers
2021-12-24
Dec 24, 2021
S
Recruiting
  • Brain Injuries
  • Bevacizumab
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital
2022-03-20
Mar 20, 2022
D
Active, not recruiting
  • Glioblastoma
  • Boston, Massachusetts
  • +4 more
2022-03-14
Mar 14, 2022
N
Recruiting
  • Metastatic Alveolar Soft Part Sarcoma
  • Unresectable Alveolar Soft Part Sarcoma
  • Phoenix, Arizona
  • +42 more
2022-02-08
Feb 8, 2022
A
Recruiting
  • Advanced Colorectal Carcinoma
  • +15 more
  • Bevacizumab
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-11-08
Nov 8, 2021
G
Recruiting
  • Glioblastoma Multiforme
  • Bevacizumab
  • Philadelphia, Pennsylvania
    (unnamed)
2022-03-14
Mar 14, 2022